A new monoclonal antibody targeting CD38 has been working its way through clinical trials. In the Phase 3 trial, Isatuximab was found to prolong progression free survival when combined with pomalidomide and dexamethasone compared to pomalidomide and dexamethasone alone.
The study, known as ICARIA-MM, enrolled 307 patients with relapsed/refractory myeloma. All participants had received lenalidomide and a proteasome inhibitor. In the trial, isatuximab was given by IV once a week for four weeks, then every other week with pomalidomide and dex.
The study results, which will be published at an upcoming medical meeting, are anticipated to help obtain regulatory approval later this year.
This is a second drug targeting CD38 (same target as daratumumab).